Fetuin-A and thyroxin binding globulin predict rituximab response in rheumatoid arthritis patients with insufficient response to anti-TNFα-Reference-Cited by-同舟云学术

Fetuin-A and thyroxin binding globulin predict rituximab response in rheumatoid arthritis patients with insufficient response to anti-TNFα

Published:2020-03-24 Issue:9 Volume:39 Page:2553-2562
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Nguyen Minh Vu Chuong,Courtier Anaïs,Adrait Annie,Defendi Federica,Couté Yohann,Baillet Athan,Guigue Lisa,Gottenberg Jacques-Eric,Dumestre-Pérard Chantal,Brun Virginie,Gaudin Philippe

Funder

Investissement d’Avenir Infrastructures Nationales en Biologie et Santé

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s10067-020-05030-6.pdf

Reference40 articles.

1. Maillefert JF, Combe B, Goupille P, Cantagrel A, Dougados M (2003) Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study. Ann Rheum Dis 62:764–766

2. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594–1602. https://doi.org/10.1056/NEJM200011303432202

3. Navarro-Millán I, Curtis JR (2013) Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis. Curr Opin Rheumatol 25:384–390. https://doi.org/10.1097/BOR.0b013e32835fc62e

4. Favalli EG, Raimondo MG, Becciolini A, Crotti C, Biggioggero M, Caporali R (2017) The management of first-line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives. Autoimmun Rev 16:1185–1195. https://doi.org/10.1016/j.autrev.2017.10.002

5. Gottenberg J-E, Brocq O, Perdriger A, Lassoued S, Berthelot JM, Wendling D, Euller-Ziegler L, Soubrier M, Richez C, Fautrel B, Constantin AL, Mariette X, Morel J, Gilson M, Cormier G, Salmon JH, Rist S, Lioté F, Marotte H, Bonnet C, Marcelli C, Sellam J, Meyer O, Solau-Gervais E, Guis S, Ziza JM, Zarnitsky C, Chary-Valckenaere I, Vittecoq O, Saraux A, Pers YM, Gayraud M, Bolla G, Claudepierre P, Ardizzone M, Dernis E, Breban MA, Fain O, Balblanc JC, Aberkane O, Vazel M, Back C, Candon S, Chatenoud L, Perrodeau E, Sibilia J, Ravaud P (2016) Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA 316:1172–1180. https://doi.org/10.1001/jama.2016.13512

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Organokines in Rheumatoid Arthritis: A Critical Review;International Journal of Molecular Sciences;2022-05-31

2. Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response for rheumatoid arthritis patients: a protocol for a randomized multicenter single-blind active controlled clinical trial (PREDIRA);Trials;2020-08-31